Lakewood-Amedex Biotherapeutics Inc. (LABT)
Nasdaq: LABT · Pharmaceutical Preparations · filing with the SEC since 2025
Who owns Lakewood-Amedex Biotherapeutics Inc.
As filed with the SECHolders of 5% or more
3
HPW Investments Holding Ltd. holds 24% of COMMON SHARES, PAR VALUE $0.0001 PER SHARE, as its SCHEDULE 13G filed Jun 23, 2026 says.
Directors and officers
5
report now, of 5 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
HPW Investments Holding Ltd.
SCHEDULE 13G · filed Jun 23, 2026 · COMMON SHARES, PAR VALUE $0.0001 PER SHARE
Lindesfarne LLC
SCHEDULE 13G · filed Aug 6, 2026 · Common Stock
WFI Equity, LLC
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock
What LABT reports owning in othersstakes of 5% or more, and other ties
Lakewood-Amedex Biotherapeutics Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
No open-market trade is on the record for these years.
Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.